BRPI0316384B8 - imunoensaio não competitivo para analitos pequenos - Google Patents

imunoensaio não competitivo para analitos pequenos

Info

Publication number
BRPI0316384B8
BRPI0316384B8 BRPI0316384A BR0316384A BRPI0316384B8 BR PI0316384 B8 BRPI0316384 B8 BR PI0316384B8 BR PI0316384 A BRPI0316384 A BR PI0316384A BR 0316384 A BR0316384 A BR 0316384A BR PI0316384 B8 BRPI0316384 B8 BR PI0316384B8
Authority
BR
Brazil
Prior art keywords
analyte
competitive immunoassay
small analytes
binding partner
binding
Prior art date
Application number
BRPI0316384A
Other languages
English (en)
Other versions
BRPI0316384B1 (pt
BR0316384A (pt
Inventor
Matti Höyhtyä
Timo Pulli
Hans SÖDERLUND
Kristiina Takkinen
Original Assignee
Valtion Teknillinen Tutkimuskeskus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8564953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0316384(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valtion Teknillinen Tutkimuskeskus filed Critical Valtion Teknillinen Tutkimuskeskus
Publication of BR0316384A publication Critical patent/BR0316384A/pt
Publication of BRPI0316384B1 publication Critical patent/BRPI0316384B1/pt
Publication of BRPI0316384B8 publication Critical patent/BRPI0316384B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format
    • G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"imunoensaio não competitivo para analitos pequenos". a invenção refere-se a um imunoensaio não competitivo para analitos pequenos, em que o analito é reagido com dois parceiros ligantes. o primeiro parceiro ligante se liga ao analito para formar um complexo entre o primeiro parceiro ligante e o analito, e o segundo parceiro ligante se liga ao complexo formado pelo primeiro parceiro ligante e o analito. o complexo resultante formado entre o analito e os parceiros ligantes é detectado. os parceiros ligantes são proteínas, tais como anticorpos incluindo fragmentos de anticorpo. a invenção refere-se ainda a pares reativos e kits de teste úteis nos ensaios, bem como ao uso dos pares reativos e a um processo para sua preparação. novos reagentes e meios para sua preparação são também providos.
BRPI0316384A 2002-11-18 2003-11-17 imunoensaio não competitivo para analitos pequenos BRPI0316384B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20022048A FI20022048A0 (fi) 2002-11-18 2002-11-18 Ei-kompetetiivinen immunomääritys pienille analyyteille
PCT/FI2003/000875 WO2004046733A1 (en) 2002-11-18 2003-11-17 Non-competitive immunoassay for small analytes

Publications (3)

Publication Number Publication Date
BR0316384A BR0316384A (pt) 2005-10-04
BRPI0316384B1 BRPI0316384B1 (pt) 2016-07-05
BRPI0316384B8 true BRPI0316384B8 (pt) 2021-07-27

Family

ID=8564953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316384A BRPI0316384B8 (pt) 2002-11-18 2003-11-17 imunoensaio não competitivo para analitos pequenos

Country Status (17)

Country Link
US (1) US7749712B2 (pt)
EP (1) EP1579222B8 (pt)
JP (1) JP4729701B2 (pt)
CN (1) CN1711476B (pt)
AT (1) ATE408146T1 (pt)
BR (1) BRPI0316384B8 (pt)
CA (1) CA2503509C (pt)
DE (1) DE60323538D1 (pt)
DK (1) DK1579222T3 (pt)
EA (1) EA200500643A1 (pt)
ES (1) ES2312828T3 (pt)
FI (1) FI20022048A0 (pt)
MX (1) MXPA05005288A (pt)
NO (1) NO338417B1 (pt)
NZ (1) NZ539714A (pt)
WO (1) WO2004046733A1 (pt)
ZA (1) ZA200503475B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109067A1 (en) 2001-12-06 2003-06-12 Immunetech, Inc. Homogeneous immunoassays for multiple allergens
JP2007040834A (ja) * 2005-08-03 2007-02-15 Japan Science & Technology Agency 免疫測定用試薬
FI20075251A0 (fi) * 2007-04-13 2007-04-13 Hytest Oy Immunomääritys epästabiilien antigeenien määrittämiseksi
GB0707870D0 (en) * 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
EP2223122B1 (en) * 2007-12-18 2011-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Endogenous morphine or a naturally occuring metabolite thereof as a marker for sepsis
GB0725234D0 (en) * 2007-12-24 2008-02-06 Oxtex Ltd Electrochemical assays
CN101981449B (zh) * 2008-04-02 2014-08-13 维瓦克塔有限公司 用于感测化学品的方法
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
FI20085579A0 (fi) * 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
DE102008049601A1 (de) * 2008-09-30 2010-04-01 Siemens Healthcare Diagnostics Products Gmbh Antikörper zur Bestimmung des Prothrombin-Fragments F2/F1+2 in einem homogenen Immunoassay
MY151976A (en) * 2009-07-21 2014-07-31 Sekisui Medical Co Ltd Insulin assay
WO2011053783A2 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
EP2515110B1 (en) * 2009-11-19 2015-03-25 Ushio Denki Kabushiki Kaisha Fluoroimmunoassay method
US8883978B2 (en) 2010-05-11 2014-11-11 Institute For Cancer Research Antibodies to tumor endothelial marker 7R
EP2759551B1 (en) * 2011-09-21 2019-05-22 Fujirebio Inc. Antibodies binding to an affinity complex comprising 25oh vitamin d2 or d3 and an antibody thereto
CA2853103C (en) * 2011-10-21 2020-01-07 Decimadx, Llc Point-of-care immunoassay for quantitative small analyte detection
EP2637021A1 (de) 2012-03-06 2013-09-11 Securetec Detektions-Systeme AG Verfahren und Vorrichtung zum Nachweis von Analyten
US9804161B1 (en) * 2012-05-14 2017-10-31 Lawrence Livermore National Security, Llc Detector and related, devices, methods and systems
EP2722669A1 (de) 2012-10-22 2014-04-23 Securetec Detektions-Systeme AG Verfahren und Vorrichtung zum Nachweis von illegalen Drogen
JP6673895B2 (ja) 2014-03-21 2020-03-25 エスティー アンド ティー インターナショナル，インコーポレイティド アサ属抽出方法及び組成物
FI126746B (en) 2014-04-07 2017-05-15 Teknologian Tutkimuskeskus Vtt Oy Antibody to HT-2 Toxin-HT-2 Toxin Antibody Complex
EP3353547A1 (en) * 2015-09-22 2018-08-01 Delta TM Technologies Designing customized protein-specific buffer systems
US10954500B2 (en) 2015-10-23 2021-03-23 Fred Hutchinson Cancer Research Center Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
CN108779169B (zh) * 2015-12-21 2022-06-07 图尔库大学 针对包含蓝细菌环肽肝毒素的免疫复合物的抗体
WO2017127833A1 (en) * 2016-01-22 2017-07-27 Affimedix, Inc. Device for detection of vitamin d metabolites
CN109863406B (zh) * 2016-07-29 2023-04-14 Diazyme研究室有限公司 用于测定维生素d的方法和成分
CN118459596A (zh) 2019-12-27 2024-08-09 凯奥目生物科学株式会社 抗cdcp1抗体
KR20230058408A (ko) 2020-09-02 2023-05-03 고쿠리츠다이가쿠호우진 도쿄다이가쿠 암 면역 미세 환경 조절 물질 및 그에 따른 예방·진단·치료적 이용
CA3239740A1 (en) * 2021-12-03 2023-06-08 Tim C. LEUTKENS High selective cd229 antigen binding domains and methods of use
JPWO2024024565A1 (pt) 2022-07-28 2024-02-01
CN117031003A (zh) * 2023-07-25 2023-11-10 深圳市科曼医疗设备有限公司 醛固酮化学发光免疫检测试剂盒
WO2025202545A1 (en) * 2024-03-27 2025-10-02 Turun Yliopisto Immunocomplex antibodies and non-competitive immunoassay for the detection of testosterone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US5223441A (en) 1986-10-09 1993-06-29 Syntex (U.S.A.) Inc. Receptors for immune complexes
JPH10507341A (ja) 1994-03-30 1998-07-21 アイジェン， インコーポレイテッド ファージ技術を用いる触媒性抗体の単離および産生
JP3025633B2 (ja) 1995-12-05 2000-03-27 株式会社蛋白工学研究所 グルタチオン結合活性を有するポリペプチド及びその製造方法
JP4228095B2 (ja) 1999-12-17 2009-02-25 東ソー株式会社 免疫測定方法および免疫測定試薬
CN1136450C (zh) * 2000-11-03 2004-01-28 厦门大学 具有荧光共振能量转移特征的成对蛋白及其用途

Also Published As

Publication number Publication date
EP1579222B1 (en) 2008-09-10
CN1711476A (zh) 2005-12-21
NZ539714A (en) 2007-03-30
CA2503509C (en) 2013-02-05
DE60323538D1 (de) 2008-10-23
MXPA05005288A (es) 2005-08-16
BRPI0316384B1 (pt) 2016-07-05
ZA200503475B (en) 2006-07-26
EP1579222B8 (en) 2009-01-07
US20060246506A1 (en) 2006-11-02
FI20022048A0 (fi) 2002-11-18
NO338417B1 (no) 2016-08-15
JP4729701B2 (ja) 2011-07-20
ATE408146T1 (de) 2008-09-15
EP1579222A1 (en) 2005-09-28
ES2312828T3 (es) 2009-03-01
CA2503509A1 (en) 2004-06-03
NO20052849L (no) 2005-06-13
WO2004046733A1 (en) 2004-06-03
BR0316384A (pt) 2005-10-04
JP2006506634A (ja) 2006-02-23
US7749712B2 (en) 2010-07-06
AU2003282143A1 (en) 2004-06-15
CN1711476B (zh) 2010-09-08
DK1579222T3 (da) 2008-11-17
EA200500643A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
BRPI0316384B8 (pt) imunoensaio não competitivo para analitos pequenos
WO2002090983A3 (de) Quantitaver einschritt immuntest in lyophilisierter form
WO2007035633A3 (en) Screening assays and methods
DE502004011867D1 (de) Analytischer Sandwichtest zur Bestimmung von NT-proBNP
WO2005061547A3 (en) Bispecific antibodies
EP2551671A3 (en) Immunoassay device with immuno-reference electrode
DE60222816D1 (de) Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
WO2004025248A3 (en) Antibody pair screening methods
WO2006102200A3 (en) Docetaxel immunoassay
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2004106385A3 (en) Monoclonal antibodies specific for buprenorphine and metabolites thereof
EP1072888A3 (en) Immunoassay method and reagent for HIV-1p24 antigen
WO2006015098A3 (en) Taxol immunoassay
WO2006020263A3 (en) Cytoxan antibodies and immunoassay
ATE466884T1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
NO20052870D0 (no) Immunoanalysemetode og sett for anvendelse derav
WO2001063285A3 (de) Verfahren zum nachweis von helicobacter pylori und heilmanii
ATE108907T1 (de) Bestimmungsverfahren, seine verwendung und komponenten.
NO903820D0 (no) Fremgangsmaate for paavisning av analytter.
DE60122306D1 (de) Antikörper, die spezifisch für freies inaktives psa sind, und ihre verwendungen
ATE437362T1 (de) Ig-assay
WO2006138694A3 (en) Rabbit monoclonal antibody against id1 protein
WO2007066231A3 (en) Rapid elisa
YU56001A (sh) Postupak semikvantitativne adsorpcije antitela prema blastokonidijama candida albicans

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2801 DE 10/09/2024 POR TER SIDO INDEVIDA.